Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06068530 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mass Vaccine and Drug Administration, Bangladesh

Study acronym: MVDA
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description expanded, about 14 wordsv5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 1, 2024 to Feb 15, 2025
    • Site details revised at 2 of 2 sites
    v4
  3. Start date: Feb 1, 2024 to May 1, 2024v3
  4. Start date: Nov 1, 2023 to Feb 1, 2024
    • Primary and study completion dates: Sep 1, 2027 to Feb 1, 2028
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass vaccinations and drug administrations versus the current standard of care.
Trial Details
NCT Number NCT06068530
Lead Sponsor University of Oxford
Conditions
(from sponsor)		 Plasmodium Falciparum Malaria
Related terms Malaria, Falciparum
Enrollment 10,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov